A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines Marie WosnyStefanie AeppliJanna Hastings Systematic Review Open access 10 June 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib Fenneke ZwierengaM. Benthe Muntinghe-WagenaarAnthonie J. van der Wekken Original Research Article Open access 05 June 2025
A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors Lillian L. SiuDavid S. HongBoon Cher Goh Original Research Article 04 June 2025
Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma Aleksandra WieczorekKatarzyna ŚladowskaHolger N. Lode Systematic Review Open access 03 June 2025
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy Phillip H. KuoJeremie CalaisMike Crosby Review Article Open access 26 May 2025
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation Fred SaadAndrew J. ArmstrongNoel W. Clarke Review Article Open access 21 May 2025 Pages: 445 - 466
Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective Tomas Buchler Review Article Open access 16 May 2025
Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma Yue GuoJin NiuNahor Haddish-Berhane Original Research Article Open access 07 May 2025
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer Erika P. HamiltonRinath M. JeselsohnSara A. Hurvitz Review Article Open access 06 May 2025 Pages: 431 - 444
Efficacy of First-Line Treatments for Advanced Renal Cell Carcinoma: A Bayesian Network Meta-analysis of Objective Response, Progression-Free Survival, and Overall Survival Manuela SchmidingerPratik P. RaneAvivit Peer Systematic Review 06 May 2025 Pages: 375 - 387
Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma Zaina S. KretRyan J. SwederGabriel Tinoco Review Article Open access 27 April 2025 Pages: 485 - 502
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure Kenji MorimotoTadaaki YamadaKoichi Takayama Original Research Article 24 April 2025 Pages: 531 - 541
The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials Giada PinterpeFortuna MigliaccioRoberto Iacovelli Systematic Review 17 April 2025 Pages: 405 - 418
Navigating the Landscape of Resistance Mechanisms in Antibody–Drug Conjugates for Cancer Treatment Gloria LalliIlaria SabatucciDomenica Lorusso Leading Article 15 April 2025 Pages: 419 - 430
Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis Erman AkkusHatime Arzu YasarAngela Lamarca Systematic Review 13 April 2025 Pages: 389 - 403
Immunotherapy for Renal Cell Carcinoma—What More is to Come? Zachary A. YochumDavid A. Braun Review Article (Invited) 10 April 2025 Pages: 467 - 483
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial Jose De La CerdaLaurence BelkoffNeal Shore Original Research Article Open access 04 April 2025 Pages: 503 - 517
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors Cathy EngNehal J. LakhaniJ. Randolph Hecht Original Research Article Open access 26 March 2025 Pages: 519 - 530
CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant—A Podcast Marcos de LimaDavid I. Marks Commentary Open access 20 March 2025 Pages: 371 - 374
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study Jean MourlanetteGaelle Rousseau-BussacJulien Mazieres Original Research Article Open access 13 March 2025 Pages: 311 - 317
Correction: Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence José Ángel García-SaenzÁlvaro Rodríguez-LescureAntonio Llombart Correction Open access 10 March 2025 Pages: 215 - 215
Differential Disease Behavior of Immune-Mediated Colitis Among Different Types of Immune Checkpoint Inhibition Malek ShatilaFarzin EshaghiYinghong Wang Original Research Article 04 March 2025 Pages: 339 - 347
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review David B. MiklosPeter A. RiedellStephen J. Schuster Review Article Open access 04 March 2025 Pages: 217 - 234
The Development of ATM Inhibitors in Cancer Therapy Elizabeth A. AmpoliniJudit Jimenez-SainzDavid T. Long Review Article Open access 01 March 2025 Pages: 281 - 297
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma Mohamed ElmeliegyAndrea ViqueiraDiane Wang Original Research Article Open access 25 February 2025 Pages: 349 - 359
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions Silvia CameraFederico RossariAndrea Casadei-Gardini Review Article 22 February 2025 Pages: 269 - 280
Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events Malek ShatilaAntonio Pizuorno MachadoYinghong Wang Original Research Article 04 February 2025 Pages: 329 - 337
The User’s Guide to Amivantamab Danielle BrazelJanellen SmithMisako Nagasaka Review Article Open access 04 February 2025 Pages: 235 - 245
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options Sarah MettiasAdam ElSayedJames R. Berenson Review Article 29 January 2025 Pages: 247 - 267
Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Real-World Experience at Hospitals in Spain Miguel Angel Rodríguez SagradoJavier Alvarez CriadoMaria José Vazquez Castillo Original Research Article 24 January 2025 Pages: 319 - 327
Bosutinib for the Treatment of CML—Using it Safely: a Podcast Jeffrey H. LiptonJorge E. Cortes Commentary Open access 17 January 2025 Pages: 183 - 189
Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study Antoine DesiletsJustin LucasDenis Soulières Original Research Article 14 January 2025 Pages: 299 - 310
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial Hua XuXin YaoDingwei Ye Original Research Article 13 January 2025 Pages: 113 - 125
Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence José Ángel García-SaenzÁlvaro Rodríguez-LescureAntonio Llombart Review Article Open access 13 January 2025 Pages: 191 - 213
Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach Michael J. SorichArkady T. Manning-BennettAshley M. Hopkins Original Research Article Open access 07 January 2025 Pages: 361 - 369
FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies David J. BenjaminAlain C. Mita Review Article 17 December 2024 Pages: 1 - 11
Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies Hui-Chen SuHo-Wei LinKa-Wai Tam Systematic Review 10 December 2024 Pages: 71 - 88
Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials Chiara CiccareseMatteo BaucknehtRoberto Iacovelli Systematic Review 29 November 2024 Pages: 103 - 112
Immunotherapy Following Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients with Anaplastic Lymphoma Kinase‑Positive Non‑small Cell Lung Cancer in Japan Yuki ShimomuraMegumi MizutaniAyumi Shintani Original Research Article 28 November 2024 Pages: 171 - 180
Unveiling the Digital Evolution of Molecular Tumor Boards Sebastian LutzAlicia D’AngeloZaynab Hammoud Review Article Open access 28 November 2024 Pages: 27 - 43
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors Manish R. PatelGerald S. FalchookErika P. Hamilton Original Research Article Open access 19 November 2024 Pages: 127 - 138
IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma Shriya DeshmukhCiara KellyGabriel Tinoco Review Article 15 November 2024 Pages: 13 - 25
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis Takafumi YanagisawaKeiichiro MoriEuropean Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU) Systematic Review 13 November 2024 Pages: 57 - 69
Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study Stephen J. FreedlandLuis FernandesCarmen Mir Original Research Article Open access 10 November 2024 Pages: 139 - 148
Delayed Separation of Kaplan–Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-Analysis Do-Youn OhNana RokutandaMelissa L. Johnson Systematic Review Open access 10 November 2024 Pages: 45 - 56
Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study Hiroshi DoiYukinori MatsuoKyoto Radiation Oncology Study Group (KROSG) Original Research Article 07 November 2024 Pages: 161 - 169
Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy Doran KsienskiPauline T. TruongSuganija Lakkunarajah Original Research Article 04 November 2024 Pages: 149 - 160
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial Erika P. HamiltonGerald S. FalchookBob T. Li Original Research Article Open access 01 November 2024 Pages: 879 - 892
Risk and Benefit for Basket Trials in Oncology: A Systematic Review and Meta-Analysis Katarzyna KlasKarolina StrzebonskaMarcin Waligora Systematic Review Open access 26 October 2024 Pages: 89 - 101
